Debridement Denials Are Up. Here's the 2026 Reason Why

A wound care program had its billing dialed in for years. Debridement codes, skin substitute application, modifier pairing, all of it ran smoothly. Then January 1, 2026 arrived, and the revenue cycle team spent the next month relearning how to bill the exact same clinical work.

That disruption was not a fluke. It was the most significant wound care reimbursement change in years, and it changed what a clean claim looks like almost overnight.

What Actually Changed on January 1

CMS reclassified skin substitute products from biologic-like therapies to incident-to medical supplies, cutting Medicare Physician Fee Schedule payment for these products by roughly 90% and replacing product-specific pricing with a single national flat rate of about $127 per square centimeter. Under the prior system, reimbursement for a single product could range from roughly $200 to more than $3,000 per square centimeter depending on which product was selected. That variability is gone, replaced by one number every practice has to hit margin targets against.

CMS also withdrew its finalized Local Coverage Determinations for skin substitute grafts used in diabetic foot ulcer and venous leg ulcer treatment, which means coverage criteria in some Medicare Administrative Contractor jurisdictions remain in flux even as the flat payment rate itself is locked in. That combination, stable pricing but unstable coverage criteria, is exactly the kind of environment where denials spike.

Where Debridement Claims Specifically Get Caught

Debridement and skin substitute application are billed together in most wound encounters, which means an error on one code can drag down reimbursement for the entire visit. Reimbursement under the 2026 rule is now limited strictly to the portion of product actually applied to the patient, with discarded or unused material no longer separately billable. A practice that does not document waste precisely is quietly underbilling every graft application, not just risking a denial.

Product-to-code mapping is the other major risk point. Every skin substitute has to be mapped to its correct FDA regulatory pathway, whether 361 HCT/P, 510(k), PMA, or 351 BLA, to determine the right HCPCS code. Any mismatch between the product's FDA classification and the billed code increases both audit risk and denial exposure under the new rule.

Rebuilding the RCM Process Around the New Rate

Practices that adapted fastest to the January 2026 change did not just update a fee schedule. They rebuilt their front-end documentation and billing checks around the new rules entirely. A handful of those checks matter most.

These are the specific controls worth auditing against your current wound care billing workflow, since several of them are new requirements under the January 2026 rule rather than holdovers from the prior system.

• Run a margin analysis on acquisition cost versus the flat reimbursement rate. With product-specific pricing gone, product selection now has a direct, calculable margin impact per application.
• Audit product-to-code mapping against FDA regulatory pathway. Every product in inventory needs to be matched to the correct HCPCS code under its FDA classification.
• Document applied versus discarded product precisely. Only the applied portion is billable under the 2026 rule, making waste documentation a revenue issue, not just a compliance one.
• Confirm coverage criteria by Medicare Administrative Contractor jurisdiction. LCD withdrawal means coverage rules now vary by region even though the payment rate does not.
• Generate ABNs before the graft is applied, referencing the specific coverage concern. A vague or post-service ABN has no legal standing under CMS's own guidance.
• Pair debridement and skin substitute coding review as one workflow, not two. An error in either code affects the reimbursement of the full visit.

What This Means for Your Existing Product Inventory

Practices carrying inventory purchased under the old pricing structure face a specific transition problem: products acquired at a higher cost basis are now reimbursed at the same flat rate as lower-cost alternatives. That makes the margin analysis on current inventory an immediate priority, not a task for next quarter's budget review, since every application from existing stock is now being billed against a rate that may not reflect what the practice paid for it.

A Rules Engine That Updates With CMS, Not After It

The practices absorbing the January 2026 change with the least disruption were running billing platforms where the rules engine updates coverage and coding logic centrally, rather than relying on every biller to memorize the new flat rate and mapping requirements individually.

ADS supports podiatry and wound care practices with purpose-built RCM that reflects current CMS policy directly in the billing workflow, helping clients hold a nearly 99% first-pass clean claim rate through a reimbursement reset that caught much of the industry flat-footed.

The flat rate is here to stay. Denials from it do not have to be.

Want to know how the January 2026 skin substitute changes affect your margins specifically?

Download the Wound Care Reimbursement Preparation Checklist to review your billing workflow against the new flat-rate rules. Prefer a direct answer? Call an ADS wound care specialist at 1-800-899-4237 ext 2264.

Sources: CMS CY 2026 Medicare Physician Fee Schedule Final Rule (cms.gov), Association for Advancing Tissue and Biologics (aatb.org), American Podiatric Medical Association (apma.org).